Federal Register / Vol. 74, No. 140 / Thursday, July 23, 2009 / Notices 36493 

The following draft toxicological 

profile will be made available to the 

public on or about July 6, 2009. 

Document Toxicological profile CAS No. 

1 ................................................................. PERFLUOROALKYLS .................................................................................................. 000375–22–4 

000335–67–1 

001763–23–1 

All profiles issued as ‘‘Draft for Public 

Comment’’ represent ATSDR’s best 

efforts to provide important 

toxicological information on priority 

substances. We are seeking public 

comments and additional information 

that may be used to supplement this 

profile. ATSDR remains committed to 

providing a public comment period for 

these documents as the best means to 

serve public health and our clients. 

Ken Rose, 

Director, Office of Policy, Planning, and 

Evaluation, National Center for 

Environmental Health/Agency for Toxic 

Substances and Disease Registry. 

[FR Doc. E9–17529 Filed 7–22–09; 8:45 am] 

BILLING CODE 4163–70–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Toxic Substances and 

Disease Registry 

[ATSDR–254] 

Notice of Development of Set 23 

Toxicological Profiles 

AGENCY: Agency for Toxic Substances 

and Disease Registry (ATSDR), 

Department of Health and Human 

Services (HHS). 

ACTION: Notice. 

SUMMARY: This notice announces the 

development of Set 23 Toxicological 

Profiles. Set 23 Toxicological Profiles 

consists of three new drafts and two 

updated drafts. These profiles will be 

available to the public on or about 

October 17, 2009. Electronic access to 

these documents will be available at the 

ATSDR Web site: http:// 

www.atsdr.cdc.gov/toxpro2.html. 

Set 23 Toxicological Profiles 

The following toxicological profiles 

are now being developed: 

Toxicological profile CAS No. 

1. Acrylamide* ...................................................................................................................................... 79–06–1 

2. Carbon Monoxide* ........................................................................................................................... 630–08–0 

3. 1,3-Butadiene .................................................................................................................................. 106–99–0 

4. Phosphate Ester Flame Retardants* ............................................................................................... 126–73–8, 126–71–6, 78–51–3, 115–86–6, 

13674–84–5, 13674–87–8, 115–96–8 

5. Vanadium ......................................................................................................................................... 7440–62–2 

* Denotes new profile. 

SUPPLEMENTARY INFORMATION: The 

Superfund Amendments and 

Reauthorization Act of 1986 (SARA) (42 

U.S.C. 9601 et seq.) amended the 

Comprehensive Environmental 

Response, Compensation, and Liability 

Act of 1980 (CERCLA or Superfund) (42 

U.S.C. 9601 et seq.) by establishing 

certain requirements for ATSDR and the 

U.S. Environmental Protection Agency 

(EPA) with regard to hazardous 

substances that are most commonly 

found at facilities on the CERCLA 

National Priorities List (NPL). Among 

these statutory requirements is a 

mandate for the Administrator of 

ATSDR to prepare toxicological profiles 

for each substance included on the 

Priority List of Hazardous Substances 

(http://www.atsdr.cdc.gov/cercla/ 

07list.html). This list names 275 

hazardous substances that pose the most 

significant potential threat to human 

health as determined by ATSDR and 

EPA. The availability of the revised list 

of the 275 priority substances was 

announced in the Federal Register on 

March 6, 2008 (73 FR 12178). For prior 

versions of the list of substances, see 

Federal Register notices dated April 17, 

1987 (52 FR 12866); October 20, 1988 

(53 FR 41280); October 26, 1989 (54 FR 

43619); October 17, 1990 (55 FR 42067); 

October 17, 1991 (56 FR 52166); October 

28, 1992 (57 FR 48801); February 28, 

1994 (59 FR 9486); April 29, 1996 (61 

FR 18744; November 17, 1997 (62 FR 

61332); October 21, 1999 (64 FR 56792); 

October 25, 2001 (66 FR 54014); 

November 7, 2003 (68 FR 63098); and 

December 7, 2005 (70 FR 70284). 

The Set 23 Toxicological Profiles for 

1,3-Butadiene and Vanadium are 

updates of previously published profiles 

for NPL priority substances. In addition, 

to address emerging public health 

concerns related to substances not 

currently on the NPL, ATSDR is also 

developing Set 23 Toxicological Profiles 

for Carbon Monoxide, Acrylamide, and 

Phosphate Ester Flame Retardants. 

Carbon monoxide is a toxic gas 

produced from the incomplete 

combustion of carbon-based fuels. 

Because it is colorless and odorless, 

toxicity can occur with no indication 

that exposure is occurring. Thousands 

of hospitalizations and hundreds of 

deaths occur every year as a result of 

inadvertent exposure to carbon 

monoxide. Acrylamide is a known 

animal carcinogen that is widely used in 

industry to synthesize polyacrylamides. 

Acrylamide also occurs naturally in a 

few foods, is formed in many foods as 

a byproduct of numerous cooking 

processes, and has been detected 

recently in human biomonitoring 

studies. Phosphate ester flame 

retardants comprise a large group of 

structurally related chemicals with 

increasing uses in clothing, fabrics, 

furniture, and structural components. 

However, there is an increasing body of 

information regarding exposures, body 

burdens, and toxicity related to this 

group of chemicals. 


erowe on DSK5CLS3C1PROD with NOTICES
36494 Federal Register / Vol. 74, No. 140 / Thursday, July 23, 2009 / Notices 

Notice of the availability of drafts of 

these two updated and three new 

toxicological profiles for public review 

and comment will be published in the 

Federal Register on/or about October 

17, 2009, with notice of a 90-day public 

comment period for each profile, 

starting from the actual release date. 

Following the close of the comment 

period, chemical-specific comments 

will be addressed, and, where 

appropriate, changes will be 

incorporated into each profile. 

FOR FURTHER INFORMATION CONTACT: 

Commander Jessilynn B. Taylor, 

Division of Toxicology and 

Environmental Medicine, Agency for 

Toxic Substances and Disease Registry, 

1600 Clifton Road, NE., Mail Stop F–32, 

Atlanta, GA 30333, telephone 770–488– 

3313. 

Ken Rose, 

Director, Office of Policy, Planning and 

Evaluation, National Center for 

Environmental Health/Agency for Toxic 

Substances and Disease Registry. 

[FR Doc. E9–17527 Filed 7–22–09; 8:45 am] 

BILLING CODE 4163–70–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Board of Scientific Counselors, 

National Center for Public Health 

Informatics (BSC, NCPHI) 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the following meeting of the 

aforementioned committee: 

Time and Date: 1 p.m.–5 p.m., August 7, 

2009 (Closed). 

Place: Teleconference. 

Status: The meeting will be closed to the 

public in accordance with provisions set 

forth in Section 552b(c)(4) and (6), Title 5 

U.S.C., and the Determination of the Director, 

Management Analysis and Services Office, 

CDC, pursuant to Public Law 92–463. 

Purpose: The committee shall advise the 

Secretary, HHS, and the Director, CDC, 

concerning strategies and goals for the 

programs and research within the national 

centers; shall conduct peer-review of 

scientific programs; and monitor the overall 

strategic direction and focus of the national 

centers. The board, after conducting its 

periodic reviews, shall submit a written 

description of the results of the review and 

its recommendations to the Director, CDC. 

The board shall perform second-level peer 

review of applications for grants-in-aid for 

research and research training activities, 

cooperative agreements, and research 

contract proposals relating to the broad areas 

within the national center. 

Matters To Be Discussed: The board will 

perform a secondary review of previously 

rated grant applications received by NCPHI 

based on RFA–HK–09–001; Centers of 

Excellence in Public Health Informatics (P01) 

and reviewed by an expert panel convened 

by NCPHI on July 22—24, 2009. 

Contact Person for More Information: Dr. 

Scott McNabb, National Center for Public 

Health Informatics, CDC, 1600 Clifton Road, 

NE., (E–78), Atlanta, Georgia 30333, 

Telephone (404) 498–6427, Fax (404) 498– 

6235. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities for 

both the CDC and the Agency for Toxic 

Substance and Disease Registry. 

Dated: July 17, 2009. 

Elaine L. Baker, 

Management Analysis and Services Office, 

Centers for Disease Control and Prevention. 

[FR Doc. E9–17524 Filed 7–22–09; 8:45 am] 

BILLING CODE 4160–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel, HIV 

Exploratory Applications. 

Date: July 28, 2009. 

Time: 11 a.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Enid Light, PhD, Scientific 

Review Officer, Division of Extramural 

Activities, National Institute of Mental 

Health, NIH, Neuroscience Center, 6001 

Executive Boulevard, Room 6132, MSC 9608, 

Bethesda, MD 20852–9608, 301–443–0322, 

elight@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.242, Mental Health Research 

Grants; 93.281, Scientist Development 

Award, Scientist Development Award for 

Clinicians, and Research Scientist Award; 

93.282, Mental Health National Research 

Service Awards for Research Training, 

National Institutes of Health, HHS) 

Dated: July 16, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–17430 Filed 7–22–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Clinical Laboratory Improvement 

Advisory Committee (CLIAC); Meeting 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC), 

announces the following meeting of the 

aforementioned committee: 

Times and Dates: 

8:30 a.m.–5 p.m., September 2, 2009. 

8:30 a.m.–3 p.m., September 3, 2009. 

Place: CDC, 1600 Clifton Road, NE., Tom 

Harkin Global Communications Center, 

Building 19, Room 232, Auditorium B, 

Atlanta, Georgia 30333. 

New Information—Online Registration 

Required: In order to expedite the security 

clearance process at the CDC Roybal Campus 

located on Clifton Road, all CLIAC attendees 

are required to register for the meeting online 

at least 14 days in advance at http:// 

wwwn.cdc.gov/cliac/default.aspx by clicking 

the ‘‘Register for a Meeting’’ link and 

completing all forms according to the 

instructions given. Please complete all the 

required fields before submitting your 

registration and submit no later than August 

19, 2009. 

Status: Open to the public, limited only by 

the space available. The meeting room 

accommodates approximately 100 people. 

Purpose: This Committee is charged with 

providing scientific and technical advice and 

guidance to the Secretary of Health and 

Human Services, the Assistant Secretary for 

Health, and the Director, CDC, regarding the 

need for, and the nature of, revisions to the 

standards under which clinical laboratories 

are regulated; the impact on medical and 

laboratory practice of proposed revisions to 

the standards; and the modification of the 

standards to accommodate technological 

advances. 

Matters To Be Discussed: The agenda will 

include agency updates from the CDC, the 

Centers for Medicare & Medicaid Services, 


erowe on DSK5CLS3C1PROD with NOTICES